CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

NCT05260957 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Refractory Non-Hodgkin Lymphoma
Relapsed Non Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma

Interventions

DRUG: Mosunetuzumab
DRUG: Polatuzumab
BIOLOGICAL: CAR-T Cell Therapy

Sponsor

Lazaros Lekakis

Collaborators

[object Object]